The president says he’s taking a stand against one of the most powerful forces in Washington. Vowing to end what he called a decades-long fleecing of the American people, Donald Trump announced Sunday that he will sign a sweeping Executive Order designed to drive down the soaring cost of prescription drugs. Set to be finalized Monday, the order would peg U.S. drug prices to the lowest rates paid by other developed nations—a move Trump called “historic” and long overdue.
In a message posted to Truth Social, the president blasted pharmaceutical companies for charging Americans “up to ten times more” for the same medications sold overseas. “It’s unfair, and it’s going to stop,” Trump wrote. “We’re finally putting American patients first.”
At the heart of the order is a “Most Favored Nation” pricing model—an aggressive policy that would force drugmakers to match their lowest global price when selling to U.S. consumers. Trump claimed the change could slash prices by as much as 80 percent and save billions in taxpayer-funded healthcare spending. “This is the kind of deal only I would make,” he said. “Others talked about it—none of them dared to do it.”
The pharmaceutical lobby, long shielded by Washington insiders, was a frequent target in Trump’s remarks. He dismissed industry claims that high domestic prices are necessary to fund research and innovation, calling that argument “a lie designed to protect obscene profits.” Trump added, “For too long, Big Pharma has taken advantage of the American people. This order puts an end to that.”
The initiative, if enforced, could also have ripple effects abroad. Trump suggested that foreign governments may soon face higher drug prices, calling it a correction to an international system that has relied on American consumers to subsidize the rest of the world. “They’ve been getting a free ride,” he said. “That ride ends now.”
The announcement has already ignited fierce debate in Washington, according to The Daily Caller. Supporters hailed the order as a long-awaited blow against monopolistic pricing, while critics—particularly within the pharmaceutical industry—warned of legal battles and possible disruptions to drug supply and innovation. But Trump remained undeterred. “They’ve had their way for too long,” he said. “This is just the beginning.”
[Read More: Two Dem Frontrunners Take Radical Stance]
